The Onco-lmaging &Spectroscopy (OIS) Program is designed to pursue basic, translational, and clinical research involving the use of biomedical imaging in the diagnosis, early-detection, molecular imaging, staging, and treatment of cancer. The imaging technologies developed within this Program include both small animal and human devices. After successful evaluation of some of the small animal imaging technologies, they are upscaled for human oncological imaging and used in translational clinical projects. The program is supported by two UCI centers, the Beckman Laser Institute (BLI) and the Center for Functional Onco-lmaging, both located on UCI's South Campus. Both of these Centers join their respective strengths to pursue a strong research program in cancer imaging through the Center. The goals of the OIS Program are multi-fold. First is to develop biophotonics technologies uniquely suited for oncological studies, focused on the application of optical measurement techniques in various types of cancer including breast, skin, and Gl for the purposes of early diagnosis and determination of therapeutic response. The second goal is to develop and validate multi-modality imaging technologies combining various different technologies such as MRI-DOT, MRI-FT, MRI-SPECT, and XCT-FT. It has been shown that such multimodality devices combine anatomical landmarks with molecular signatures for improved detection and determination of therapeutic response. The third goal is to translate the developed imaging technologies to human studies. The application of DCE-MRI is an excellent example of this effort, having been developed and validated in animal models of cancer in the mid-1990s and has been successfully applied in human studies since late 1990s. The fourth goal is to apply the developed imaging technologies in clinical trials. The OIS Program has 18 Members, representing eight Departments and three Schools, and has $4,787,231 in direct cancer-related peer-reviewed funding, six projects of which are funded by NCI for a direct total of $2,060,049. In 2007, Members published a total of 44 publications with 20 of those being cancer-related of which 65% were inter- and 65% were intra-related.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Irvine
United States
Zip Code
Rush, Christina L; Darling, Margaret; Elliott, Maria Gloria et al. (2015) Engaging Latina cancer survivors, their caregivers, and community partners in a randomized controlled trial: Nueva Vida intervention. Qual Life Res 24:1107-18
Parihar, Vipan K; Allen, Barrett D; Tran, Katherine K et al. (2015) Targeted overexpression of mitochondrial catalase prevents radiation-induced cognitive dysfunction. Antioxid Redox Signal 22:78-91
Stockler, Martin R; Hilpert, Felix; Friedlander, Michael et al. (2014) Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol 32:1309-16
Sun, Peng; Watanabe, Kazuhide; Fallahi, Magid et al. (2014) Pygo2 regulates ?-catenin-induced activation of hair follicle stem/progenitor cells and skin hyperplasia. Proc Natl Acad Sci U S A 111:10215-20
Lackford, Brad; Yao, Chengguo; Charles, Georgette M et al. (2014) Fip1 regulates mRNA alternative polyadenylation to promote stem cell self-renewal. EMBO J 33:878-89
Balu, Mihaela; Kelly, Kristen M; Zachary, Christopher B et al. (2014) Distinguishing between benign and malignant melanocytic nevi by in vivo multiphoton microscopy. Cancer Res 74:2688-97
Yonova, Ivelina M; Osborne, Charlotte A; Morrissette, Naomi S et al. (2014) Diaryl and heteroaryl sulfides: synthesis via sulfenyl chlorides and evaluation as selective anti-breast-cancer agents. J Org Chem 79:1947-53
Watanabe, K; Fallahi, M; Dai, X (2014) Chromatin effector Pygo2 regulates mammary tumor initiation and heterogeneity in MMTV-Wnt1 mice. Oncogene 33:632-42
Kim, Monica Y; Li, David Jiang; Pham, Long K et al. (2014) Microfabrication of High-Resolution Porous Membranes for Cell Culture. J Memb Sci 452:460-469
Cheng, Chunmei; Pal, Sukumar; Tifrea, Delia et al. (2014) A vaccine formulated with a combination of TLR-2 and TLR-9 adjuvants and the recombinant major outer membrane protein elicits a robust immune response and significant protection against a Chlamydia muridarum challenge. Microbes Infect 16:244-52

Showing the most recent 10 out of 289 publications